About LivaNova (NASDAQ:LIVN)
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company's segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products. Cardiac Surgery products include oxygenators, heart-lung machines, autotransfusion, mechanical heart valves and tissue heart valves. The Cardiac Rhythm Management segment is engaged in the development, manufacturing and marketing of products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure. Cardiac Rhythm Management products include high-voltage defibrillators Cardiac Resynchronization Therapy device (CRT-D) and low-voltage pacemakers. The Neuromodulation segment is engaged in the design, development and marketing of neuromodulation therapy for the treatment of drug-resistant epilepsy and treatment resistant depression.
Industry, Sector and Symbol
Industry Medical Equipment, Supplies & Distribution
Trailing P/E Ratio70.0176924589099
Forward P/E Ratio25.76
Sales & Book Value
Annual Sales$1.21 billion
Price / Sales3.25
Cash Flow$5.49 per share
Price / Cash14.93
Book Value$34.99 per share
Price / Book2.34
Return on Equity9.33%
Return on Assets6.82%
LivaNova (NASDAQ:LIVN) Frequently Asked Questions
What is LivaNova's stock symbol?
LivaNova trades on the NASDAQ under the ticker symbol "LIVN."
How were LivaNova's earnings last quarter?
LivaNova PLC (NASDAQ:LIVN) released its quarterly earnings data on Thursday, November, 2nd. The company reported $0.93 EPS for the quarter, topping the consensus estimate of $0.76 by $0.17. The business had revenue of $309.70 million for the quarter, compared to analyst estimates of $301.22 million. LivaNova had a net margin of 4.63% and a return on equity of 9.33%. The business's revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.78 EPS. View LivaNova's Earnings History.
When will LivaNova make its next earnings announcement?
What guidance has LivaNova issued on next quarter's earnings?
LivaNova updated its FY17 earnings guidance on Thursday, November, 2nd. The company provided earnings per share guidance of $3.30-3.45 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.24.
Where is LivaNova's stock going? Where will LivaNova's stock price be in 2018?
7 brokers have issued 12 month target prices for LivaNova's stock. Their forecasts range from $50.00 to $97.00. On average, they expect LivaNova's share price to reach $78.17 in the next year. View Analyst Ratings for LivaNova.
What are Wall Street analysts saying about LivaNova stock?
Here are some recent quotes from research analysts about LivaNova stock:
- 1. According to Zacks Investment Research, "LivaNova PLC is a medical technology company which focuses on providing treatment for cardiovascular diseases and neuromodulation. The Company's operating units consists of Cardiac Rhythm Management, Cardiac Surgery and Neuromodulation. LivaNova PLC, formerly known as Cyberonics, Inc., is based in London, United Kingdom. " (12/21/2017)
- 2. Canaccord Genuity analysts commented, "We remain HOLD-rated on shares of LIVN in the wake of their announcement that the company would purchase the remaining part of ImThera – an early-stage company focused on neuromodulation to treat obstructive sleep apnea – that it does not already own. While the technology fits synergistically within LIVN’s strong neuromodulation franchise to some degree, the call point will be different than its current offering (ENTs vs. neurosurgeons). The firm thinks it can leverage its growing OUS neuromodulation sales presence to drive some near-term ImThera revenue (expectations not disclosed) in Europe; however, we expect contributions will be minimal for the next few years at least, primarily on the basis of current reimbursement coverage, or lack thereof, and need for long-term data to catalyze ENT surgeons to adopt the therapy, according to our due diligence." (12/5/2017)
- 3. Needham & Company LLC analysts commented, "LIVN announced that it is exploring strategic options for its low growth and low margin CRM business. This shouldn’t come as a huge surprise since management had previously hinted a potential sale of the CRM business. We think a CRM sale would increase LIVN’s revenue growth; the EPS impact hinges on price, CRM margins, and use of proceeds. We think a sale would be neutral to slightly dilutive if the proceeds were used for share repurchases and/or debt repayment though we note that there would likely be near-term hit to EPS between when the sale is announced and when LIVN is able to deploy the proceeds to offset any dilution." (9/14/2017)
- 4. BTIG Research analysts commented, "Last week, while we were at our Snowbird conference, LIVN reported Q4 results and released initial FY17 guidance. Once again, we are lowering our estimates for LIVN. While shares are inexpensive, we do not see how it will grow in the future unless major M&A or R&D efforts take place, moving LIVN into new markets. Given most of LIVN’s markets are flat to declining, we would be inclined to wait for the company to show intentions to enter new markets before recommending shares. We don’t expect an inflection point on cardiac surgery anytime soon and while new iterations in Neuromod may pad growth in 2H17, we think the lower end of the 1-3% revenue growth guidance would be a good achievement. There remain considerable areas of opportunity on the synergy side, which should support EPS growth. With the first innings of physical integration behind them, we think the co. is in a better position to focus on more sizeable areas of savings such as purchasing/direct procurement. However, we think the lack of revenue growth is more important than synergies and we reiterate our Neutral rating." (3/10/2017)
Who are some of LivaNova's key competitors?
Some companies that are related to LivaNova include West Pharmaceutical Services (WST), Hill-Rom (HRC), DexCom (DXCM), ICU Medical (ICUI), VWR (VWR), Globus Medical (GMED), Integra Lifesciences (IART), Haemonetics (HAE), Neogen (NEOG), NuVasive (NUVA), Inogen (INGN), Nevro (NVRO), Halyard Health (HYH), MiMedx Group (MDXG), CONMED (CNMD), OraSure Technologies (OSUR), Atrion (ATRI) and Intersect ENT (XENT).
Who owns LivaNova stock?
LivaNova's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Schwab Charles Investment Management Inc. (0.53%) and Waverton Investment Management Ltd (0.23%). Company insiders that own LivaNova stock include Alfred J Novak, Daniel Jeffrey Moore, Hugh M Morrison, Jacques Gutedel, Sharon O'kane and Two SCA Equinox. View Institutional Ownership Trends for LivaNova.
Who sold LivaNova stock? Who is selling LivaNova stock?
LivaNova's stock was sold by a variety of institutional investors in the last quarter, including Waverton Investment Management Ltd. Company insiders that have sold LivaNova company stock in the last year include Alfred J Novak, Daniel Jeffrey Moore and Hugh M Morrison. View Insider Buying and Selling for LivaNova.
Who bought LivaNova stock? Who is buying LivaNova stock?
How do I buy LivaNova stock?
Shares of LivaNova can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is LivaNova's stock price today?
One share of LivaNova stock can currently be purchased for approximately $81.92.
How big of a company is LivaNova?
LivaNova has a market capitalization of $3.90 billion and generates $1.21 billion in revenue each year. The company earns $-62,780,000.00 in net income (profit) each year or $1.17 on an earnings per share basis. LivaNova employs 4,500 workers across the globe.
How can I contact LivaNova?
LivaNova's mailing address is 20 EASTBOURNE TERRACE, LONDON X0, W2 6LG. The company can be reached via phone at 44-0-20-3325-0660 or via email at [email protected]
MarketBeat Community Rating for LivaNova (LIVN)MarketBeat's community ratings are surveys of what our community members think about LivaNova and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
LivaNova (NASDAQ:LIVN) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Hold||Hold||Hold||Hold|
|Consensus Rating Score: ||2.43||2.43||2.43||2.25|
|Ratings Breakdown: ||1 Sell Rating(s)|
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$78.17||$78.17||$71.50||$61.33|
|Price Target Upside: ||6.54% downside||6.54% downside||4.70% upside||24.62% upside|
LivaNova (NASDAQ:LIVN) Consensus Price Target History
LivaNova (NASDAQ:LIVN) Analyst Ratings History
(Data available from 1/19/2016 forward)
LivaNova (NASDAQ:LIVN) Earnings History and Estimates Chart
LivaNova (NASDAQ LIVN) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/7/2018|| || || || || || || || |
|11/2/2017||Q3 2017||$0.76||$0.93||$301.22 million||$309.70 million||View||N/A|
|8/9/2017||Q2 2017||$0.82||$1.01||$315.75 million||$321.40 million||View||Listen|
|3/1/2017||Q416||$0.79||$0.82||$301.45 million||$310.60 million||View||Listen|
|11/2/2016||Q316||$0.76||$0.78||$299.40 million||$295.30 million||View||N/A|
LivaNova (NASDAQ:LIVN) Earnings Estimates
2018 EPS Consensus Estimate: $3.70
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for LivaNova (NASDAQ:LIVN)
No dividend announcements for this company have been tracked by MarketBeat.com
LivaNova (NASDAQ LIVN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.28%
Institutional Ownership Percentage: 86.00%
LivaNova (NASDAQ LIVN) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|1/16/2018||Daniel Jeffrey Moore||Director||Sell||1,000||$82.15||$82,150.00|| |
|12/15/2017||Daniel Jeffrey Moore||Director||Sell||1,000||$80.80||$80,800.00|| |
|11/29/2017||Hugh M Morrison||Director||Sell||1,830||$88.00||$161,040.00|| |
|11/22/2017||Alfred J Novak||Director||Sell||2,000||$85.77||$171,540.00|| |
|11/15/2017||Daniel Jeffrey Moore||Director||Sell||1,000||$81.39||$81,390.00|| |
|10/16/2017||Daniel Jeffrey Moore||Director||Sell||1,000||$74.58||$74,580.00|| |
|9/15/2017||Daniel Jeffrey Moore||Director||Sell||1,000||$68.55||$68,550.00||57,296|| |
|8/15/2017||Daniel Jeffrey Moore||Director||Sell||1,000||$60.76||$60,760.00||58,296|| |
|7/17/2017||Daniel Jeffrey Moore||Director||Sell||1,000||$61.55||$61,550.00||56,437|| |
|6/15/2017||Daniel Jeffrey Moore||Director||Sell||1,000||$60.80||$60,800.00||57,437|| |
|5/23/2017||Sharon O'kane||Director||Buy||1,000||$58.58||$58,580.00||1,000|| |
|5/22/2017||Alfred J Novak||Director||Sell||1,000||$58.49||$58,490.00||12,020|| |
|5/5/2017||Hugh M Morrison||Director||Sell||3,215||$55.89||$179,686.35||2,000|| |
|4/17/2017||Daniel Jeffrey Moore||Director||Sell||1,000||$51.32||$51,320.00||59,437|| |
|3/15/2017||Daniel Jeffrey Moore||Director||Sell||1,000||$50.21||$50,210.00||60,437|| |
|9/22/2016||Two S.C.A. Equinox||Major Shareholder||Sell||185,000||$61.54||$11,384,900.00|| |
|9/21/2016||Two S.C.A. Equinox||Major Shareholder||Sell||391,379||$60.69||$23,752,791.51|| |
|9/16/2016||Two S.C.A. Equinox||Major Shareholder||Sell||75,213||$59.86||$4,502,250.18|| |
|9/13/2016||Two S.C.A. Equinox||Major Shareholder||Sell||25,408||$60.02||$1,524,988.16|| |
|9/8/2016||Two S.C.A. Equinox||Major Shareholder||Sell||208,000||$60.52||$12,588,160.00|| |
|8/9/2016||Jacques Gutedel||Insider||Sell||4,000||$60.52||$242,080.00||10,948|| |
|5/24/2016||Daniel Jeffrey Moore||Director||Sell||1,000||$50.07||$50,070.00||64,137|| |
|5/19/2016||Hugh M Morrison||Director||Sell||3,600||$48.00||$172,800.00||5,215|| |
|5/6/2016||Alfred J Novak||Director||Sell||4,000||$51.12||$204,480.00||13,020|| |
|4/15/2016||Daniel Jeffrey Moore||Director||Sell||1,000||$54.81||$54,810.00||64,437|| |
|3/15/2016||Daniel Jeffrey Moore||Director||Sell||1,000||$56.88||$56,880.00||65,437|| |
|2/16/2016||Daniel Jeffrey Moore||Director||Sell||1,000||$56.88||$56,880.00||66,437|| |
|1/15/2016||Daniel Jeffrey Moore||Director||Sell||1,000||$52.64||$52,640.00||67,437|| |
|12/15/2015||Daniel Jeffrey Moore||Director||Sell||2,500||$53.97||$134,925.00||68,437|| |
LivaNova (NASDAQ LIVN) News Headlines
|Daniel Jeffrey Moore Sells 1,000 Shares of LivaNova PLC (LIVN) Stock|
www.americanbankingnews.com - January 17 at 9:32 PM
|LivaNova PLC (LIVN) Given Average Rating of "Hold" by Analysts|
www.americanbankingnews.com - December 26 at 7:53 AM
|Globus Medical (GMED) versus LivaNova (LIVN) Financial Review|
www.americanbankingnews.com - December 24 at 1:32 PM
|LivaNova (LIVN) Stock Rating Lowered by Zacks Investment Research|
www.americanbankingnews.com - December 22 at 12:10 AM
|LivaNova Plc breached its 50 day moving average in a Bearish Manner : LIVN-US : December 21, 2017|
finance.yahoo.com - December 21 at 9:27 AM
|LivaNova (LIVN) Downgraded to "Hold" at ValuEngine|
www.americanbankingnews.com - December 20 at 10:10 PM
|Head to Head Contrast: Intersect ENT (XENT) & LivaNova (LIVN)|
www.americanbankingnews.com - December 20 at 7:14 AM
|LivaNova (LIVN) Lowered to "Buy" at BidaskClub|
www.americanbankingnews.com - December 17 at 5:20 PM
|Analyzing Globus Medical (GMED) and LivaNova (LIVN)|
www.americanbankingnews.com - December 17 at 11:32 AM
|LivaNova (LIVN) Earns "Hold" Rating from Canaccord Genuity|
www.americanbankingnews.com - December 5 at 8:48 PM
|LivaNova (LIVN) PT Raised to $97.00 at Needham & Company LLC|
www.americanbankingnews.com - December 5 at 9:46 AM
|LivaNova PLC (LIVN) Given Average Rating of "Buy" by Brokerages|
www.americanbankingnews.com - December 1 at 6:04 PM
|Insider Selling: LivaNova PLC (LIVN) Director Sells 1,830 Shares of Stock|
www.americanbankingnews.com - November 30 at 4:40 PM
|LivaNova PLC (LIVN) Director Sells $171,540.00 in Stock|
www.americanbankingnews.com - November 24 at 10:36 AM
|LivaNova Reaches Analyst Target Price|
www.nasdaq.com - November 23 at 6:08 AM
|LivaNova PLC (LIVN) Price Target Raised to $93.00|
www.americanbankingnews.com - November 21 at 8:24 AM
|BRIEF-LivaNova says breaching co to pay $6 mln if deal with Microport collapses|
finance.yahoo.com - November 20 at 4:20 PM
|LivaNova To Sell CRM Business Franchise For $190 Mln; Updates FY17 Outlook|
www.nasdaq.com - November 20 at 5:17 AM
|LivaNova Enters into Binding Letter of Intent to Sell its Cardiac Rhythm Management Business Franchise to MicroPort Scientific Corporation for $190 Million|
finance.yahoo.com - November 20 at 5:17 AM
|BRIEF-Microport Scientific's unit buys CRM business from Livanova|
finance.yahoo.com - November 20 at 5:17 AM
|LivaNova PLC (LIVN) Director Sells $81,390.00 in Stock|
www.americanbankingnews.com - November 16 at 4:50 PM
|LivaNova PLC's (LIVN) Hold Rating Reaffirmed at Canaccord Genuity|
www.americanbankingnews.com - November 14 at 11:03 PM
|LivaNova to Present at the Piper Jaffray and Berenberg Conferences|
finance.yahoo.com - November 8 at 2:01 PM
|LivaNova PLC (LIVN) Receives Consensus Recommendation of "Hold" from Analysts|
www.americanbankingnews.com - November 6 at 8:04 AM
|FY2017 Earnings Estimate for LivaNova PLC Issued By Jefferies Group (LIVN)|
www.americanbankingnews.com - November 6 at 4:36 AM
|LivaNova PLC (LIVN) Given New $89.00 Price Target at Needham & Company LLC|
www.americanbankingnews.com - November 5 at 8:56 PM
|Jefferies Group LLC Boosts LivaNova PLC (LIVN) Price Target to $91.00|
www.americanbankingnews.com - November 5 at 10:06 AM
|LivaNova PLC's (LIVN) "Buy" Rating Reiterated at Piper Jaffray Companies|
www.americanbankingnews.com - November 3 at 10:46 PM
|Livanova PLC to Host Earnings Call|
finance.yahoo.com - November 3 at 7:52 PM
|LivaNova PLC (LIVN) Raised to Buy at ValuEngine|
www.americanbankingnews.com - November 3 at 12:46 AM
|LivaNova PLC (LIVN) Issues Earnings Results|
www.americanbankingnews.com - November 2 at 6:44 PM
|Reviewing Nevro Corp. (NVRO) & LivaNova PLC (LIVN)|
www.americanbankingnews.com - November 2 at 3:18 PM
|LivaNova PLC (LIVN) Updates FY17 Earnings Guidance|
www.americanbankingnews.com - November 2 at 9:52 AM
|LivaNova Recognizes Epilepsy Awareness Month This November|
finance.yahoo.com - November 2 at 5:36 AM
|LivaNova PLC (LIVN) & Its Peers Critical Review|
www.americanbankingnews.com - October 31 at 1:06 PM
|LivaNova PLC (LIVN) Scheduled to Post Quarterly Earnings on Thursday|
www.americanbankingnews.com - October 26 at 5:00 AM
|ETFs with exposure to LivaNova Plc : October 20, 2017|
finance.yahoo.com - October 21 at 6:10 AM
|LivaNova PLC (LIVN) vs. Its Rivals Financial Contrast|
www.americanbankingnews.com - October 21 at 4:24 AM
|LivaNova PLC (LIVN) Given Average Recommendation of "Hold" by Brokerages|
www.americanbankingnews.com - October 12 at 6:58 AM
|ETFs with exposure to LivaNova Plc : October 9, 2017|
finance.yahoo.com - October 9 at 4:29 PM
|LivaNova Plc :LIVN-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017|
finance.yahoo.com - October 7 at 2:36 AM
|Head to Head Analysis: LivaNova PLC (LIVN) versus Its Competitors|
www.americanbankingnews.com - October 4 at 2:36 PM
|LivaNova and MicroPort Announce the Approval of Rega Pacemakers by the China Food and Drug Administration|
finance.yahoo.com - September 28 at 1:58 AM
|LivaNova Announces U.S. Launch of Optiflow Arterial Cannulae Family|
finance.yahoo.com - September 25 at 7:03 PM
|Head-To-Head Survey: LivaNova PLC (LIVN) versus CryoLife (CRY)|
www.americanbankingnews.com - September 25 at 2:36 PM
|LivaNova PLC (LIVN) Stock Rating Reaffirmed by Canaccord Genuity|
www.americanbankingnews.com - September 20 at 9:42 AM
|LivaNova PLC (LIVN) Director Daniel Jeffrey Moore Sells 1,000 Shares|
www.americanbankingnews.com - September 19 at 4:28 PM
|LivaNova PLC (LIVN) Receives Consensus Rating of "Hold" from Analysts|
www.americanbankingnews.com - September 17 at 9:02 AM
|LivaNova PLC (LIVN) Lifted to Buy at Needham & Company LLC|
www.americanbankingnews.com - September 16 at 8:26 PM
|LivaNova PLC (LIVN) PT Raised to $80.00|
www.americanbankingnews.com - September 15 at 2:34 PM
LivaNova (NASDAQ:LIVN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
LivaNova (NASDAQ:LIVN) Income Statement, Balance Sheet and Cash Flow Statement
LivaNova (NASDAQ LIVN) Stock Chart for Friday, January, 19, 2018